Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy

被引：0
|
作者：
Gold, Linda Stein [1 ]
Kircik, Leon [2 ,3 ,4 ]
Sugarman, Jeffrey [5 ]
Lin, Tina [6 ]
Pillai, Radhakrishnan [7 ]
Varughese, Johnson [7 ]
机构：
[1] Henry Ford Hosp, Detroit, MI 48202 USA
[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[3] Phys Skin Care PLLC, Louisville, KY USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Ortho Dermatol, Bridgewater, NJ USA
[7] Bausch Hlth, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9859
引用
收藏
页码：AB69 / AB69
页数：1
相关论文
共 50 条
  • [41] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [42] Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials
    Gold, Linda Stein
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Pariser, David M.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 287 - 293
  • [43] Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity
    Bhatia, Neal
    Weiss, Jonathan S.
    Sadick, Neil
    Cook-Bolden, Fran E.
    Tyring, Stephen K.
    Guenin, Eric
    Loncaric, Anya
    Harris, Susan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (07) : 727 - 734
  • [44] Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)
    Gold, Linda Stein
    Lain, Edward
    Bagel, Jerry
    Jacobson, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB156 - AB156
  • [45] Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Lin, Tina
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (10) : 1012 - 1018
  • [46] Advances in the treatment of moderate-to-severe plaque psoriasis
    Herrier, Richard N.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (09) : 795 - 806
  • [47] Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
    Tanghetti, Emil A.
    Werschler, William P.
    Lain, Terry
    Guenin, Eric
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (01) : 70 - 77
  • [48] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [49] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
  • [50] Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex
    Kircik, Leon H.
    Gold, Linda Stein
    Beer, Kenneth
    Tan, Jerry
    Baldwin, Hilary
    Guenin, Eric
    Kang, Robert
    Varughese, Johnson
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 777 - 783
12345